Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

NCT03364738 | Terminated Phase 3 Results FDA Drug

• 2 other identifiers: SHP634-4042017-003067-36
• Study Type: interventional
• Target: 22
• Locations: 4 countries
• Sites: 10

Brief Summary

This study is open to adults with hypoparathyroidism who complete the SHP634-101 study (PARALLAX Study). The purpose of this study is to see if rhPTH(1-84) is safe and effective in adults with hypoparathyroidism who previously participated in the SHP634-101 study. All participants enrolled in this study will receive rhPTH(1-84) once-daily for 52 weeks via an injection. Patients who complete the SHP634-101 study will have the option to screen for this extension study.

Conditions

Hypoparathyroidism

Outcome Measures

Primary Outcomes (10)

• Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (>=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (<=) Upper Limit of Normal (ULN) at Week 24

  Percentage of participants who achieved ACSC values \>= to range of 1.875 mmol/L and \<= ULN at Week 24 was reported.

  At Week 24

• Percentage of Participants With Total ACSC Values >= to the Range of 7.5 mg/dL (1.875 mmol/L) and <=ULN at Week 52 (End-of-treatment [EOT])

  Percentage of participants who achieved ACSC values \>= to range of 1.875 mmol/L and \<= ULN at Week 52 (EOT) was reported.

  At Week 52 (EOT)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

  An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.

  From start of study drug administration to end of study (Week 56)

• Number of Participants With Clinically Significant Change in Clinical Laboratory Values

  Clinical laboratory assessment included hematology, serum chemistry, urine chemistry and urinalysis. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in clinical laboratory results which were deemed clinically significant by the investigator was reported.

  From start of study drug administration to end of study (Week 56)

• Number of Participants With Clinically Significant Change in Vital Sign

  Vital sign parameters included: temperature, pulse rate, respiration rate, systolic and diastolic blood pressure. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in vital signs which were deemed clinically significant by the investigator was reported.

  From start of study drug administration to end of study (Week 56)

• Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters

  Twelve-lead ECGs was performed in triplicate with a minimum 2-minute gap between traces. The participant rested in the supine position for at least 5 minutes before collecting the ECG. Assessment of ECG parameters included: heart rate, RR interval, PR interval, QRS interval, QT interval, and QTc interval. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any change in ECG assessments which were deemed clinically significant by the investigator was reported.

  From start of study drug administration to end of study (Week 56)

• Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values

  eGFR was calculated using the chronic kidney disease epidemiology (CDK-epi) formula. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in eGFR assessments which were deemed clinically significant by the investigator was reported.

  From start of study drug administration to end of study (Week 56)

• Number of Participants With Clinically Significant Change in Serum Creatinine Value

  eGFR was assessed by measuring serum creatinine. Serum creatinine level was obtained directly from laboratory results. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in serum creatinine assessments which were deemed clinically significant by the investigator was reported.

  From start of study drug administration to end of study (Week 56)

• Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 24

  Number of participants with positive anti-parathyroid hormone antibodies at Week 24 was reported.

  Week 24

• Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 52 (EOT)

  Number of participants with positive anti-parathyroid hormone antibodies at Week 52 (EOT) was reported.

  Week 52 (EOT)

Secondary Outcomes (11)

• Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT)

  Baseline, Weeks 24 and 52 (EOT)

• Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

  Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

• Change From Baseline in ACSC-phosphate Product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

  Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

• Change From Baseline in 24-hour Urine Calcium Excretion at Weeks 16, 32 and 52 (EOT)

  Baseline, Weeks 16, 32 and 52 (EOT)

• Percentage Change From Baseline in Prescribed Supplemental Oral Calcium Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (End of Study [EOS])

  Baseline and at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)

Study Arms (1)

rhPTH(1-84)

EXPERIMENTAL

Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter \[mg/dL\]). Once a participant achieves a stable ACSC (2-2.25 mmol/L \[8.0-9.0mg/dL\]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (\>) 2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be administered.

Biological: rhPTH(1-84)

Interventions

rhPTH(1-84) BIOLOGICAL

Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.

rhPTH(1-84)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• An understanding, ability, and willingness to fully comply with study procedures and restrictions
• Ability to voluntarily provide written, signed, and dated informed consent to participate in the study.
• Previously completed the SHP634-101 (NCT02781844) study, including the 30-day follow-up.
• Male or non-pregnant, non-lactating female subjects who agree to comply with applicable contraceptive requirements of the protocol or females of non-childbearing potential.

You may not qualify if:

• Received investigational study drug, aside from that received in study SHP634-101 (NCT02781844), within 3 months prior to the screening visit.
• Presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine (with exception of the condition under study), or neurologic system(s) or psychiatric disease, that in the opinion of the investigator, would make the subject unsuitable for this study.
• Received parathyroid hormone (PTH), PTH analog, or parathyroid hormone fragment 1-34 \[PTH(1-34)\] treatment within the last 30 days from the screening visit.
• Subjects with a history of parathyroid hormone intolerance, based on investigator determination.
• Any disease that might affect calcium metabolism or calcium-phosphate homeostasis as determined by the investigator other than hypoparathyroidism, including but not limited to, active hyperthyroidism; poorly controlled insulin-dependent diabetes mellitus or type 2 diabetes mellitus; severe and chronic cardiac, liver or renal disease; Cushing's syndrome; neuromuscular disease such as rheumatoid arthritis; myeloma; pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy, bone metastases or a history of skeletal malignancies; primary or secondary hyperparathyroidism; a history of parathyroid carcinoma; hypopituitarism, acromegaly; or multiple endocrine neoplasia types 1 and 2 .
• Subjects who are at increased baseline risk for osteosarcoma such as subjects with Paget's disease of bone or unexplained elevations of alkaline phosphatase, young adult subjects with open epiphyses, subjects with hereditary disorders predisposing to osteosarcoma or subjects with a prior history of external beam or implant radiation therapy involving the skeleton.
• Use of the following medications prior to administration of investigational product within:
• days-loop diuretics, lithium, systemic corticosteroids (medical judgment is required by the investigator. Primarily high doses of systemic corticosteroids \[example (eg), prednisone\] should be excluded. Stable doses of hydrocortisone \[eg, as treatment for Addison's disease\] may be acceptable).
• months-cinacalcet hydrochloride
• months-fluoride tablets, oral bisphosphonates, methotrexate, growth hormone, digoxin
• months-intravenous bisphosphonates, drug or alcohol abuse, as determined by the investigator
• Presence of any clinically significant results from laboratory tests, vital signs assessments, or electrocardiograms (ECG), that in the opinion of the investigator, would make the subject unsuitable for this study.
• Any medical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for this study.
• History of a clinically significant illness during the 4 weeks prior to dosing, that in the opinion of the investigator, would make the subject unsuitable for this study.
• History of any clinically significant surgery or procedure within 8 weeks of first dose, as determined by the investigator or expected to undergo a major surgical procedure during the trial.

Sponsors & Collaborators

• Shire: lead

Study Sites (10)

University of Kentucky Medical Center

Lexington, Kentucky, 40536, United States

Location

Crescent City Clinical Research Center, LLC

Metairie, Louisiana, 70006, United States

Location

Northern Nevada Endocrinology - Lisa Abbott MD

Reno, Nevada, 89511-2060, United States

Location

Ohio State University

Columbus, Ohio, 43210, United States

Location

Thomas Jefferson University, Jefferson Rheumatology Associates

Philadelphia, Pennsylvania, 19107-6810, United States

Location

Bone Research and Education Centre

Oakville, Ontario, L6M 1M1, Canada

Location

CHU de Quebec-Universite Laval

Québec, G1V 4G2, Canada

Location

Aarhus Universitetshospital

Aarhus N, 8200, Denmark

Location

Semmelweis Egyetem

Budapest, 1083, Hungary

Location

Pecsi Tudomanyegyetem, I. sz. Belgyogyaszati Klinika

Pécs, 7624, Hungary

Location

Related Publications (1)

• Khan AA, Abbott LG, Ahmed I, Ayodele O, Gagnon C, Finkelman RD, Mezosi E, Rejnmark L, Takacs I, Yin S, Ing SW. Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism. JBMR Plus. 2024 Jan 5;8(3):ziad010. doi: 10.1093/jbmrpl/ziad010. eCollection 2024 Mar.

  PMID: 38741607 DERIVED

MeSH Terms

Conditions

Hypoparathyroidism

Condition Hierarchy (Ancestors)

Parathyroid Diseases; Endocrine System Diseases

Limitations and Caveats

The study was terminated due to Takeda commercial Natpara recall.

Results Point of Contact

• Title: Study Director
• Organization: Shire

ClinicalTransparency@takeda.com

+1 866 842 5335

Study Officials

• Study Director

  Shire

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2017
• First Posted: December 7, 2017
• Study Start: September 26, 2018
• Primary Completion: April 14, 2020
• Study Completion: April 14, 2020
• Last Updated: October 7, 2022
• Results First Posted: June 16, 2021

Record last verified: 2021-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Locations

CA (2); DK (1); HU (2); US (5)